Please use this identifier to cite or link to this item:
|Title:||Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.|
|Authors:||Vella, Laura J;Andrews, Miles C;Behren, Andreas;Cebon, Jonathan S;Woods, Katherine|
|Affiliation:||Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Cancer Immuno-biology Laboratory, Heidelberg, VIC 3084, Australia.|
|Citation:||Expert Review of Clinical Immunology 2014; 10(8): 1107-23|
|Abstract:||Metastatic malignant melanoma is a frequently fatal cancer. In recent years substantial therapeutic progress has occurred with the development of targeted kinase inhibitors and immunotherapeutics. Targeted therapies often result in rapid clinical benefit however responses are seldom durable. Immune therapies can result in durable disease control but responses may not be immediate. Optimal cancer therapy requires both rapid and durable cancer control and this can likely best be achieved by combining targeted therapies with immunotherapeutics. To achieve this, a detailed understanding of the immune consequences of the various kinase inhibitors, in development, clinical trial and currently used to treat melanoma is required.|
|Internal ID Number:||24939732|
Clinical Trials as Topic
Molecular Targeted Therapy
Protein Kinase Inhibitors.therapeutic use
Signal Transduction.drug effects
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.